I've posted the link below if anyone is interested
The first person formally treated with Recce Pharmaceutical’s (ASX:RCE) next-generation antibiotic calls it a “bloody miracle” after it cured a chronic, debilitating sinus infection he had suffered from for decades. Fletcher, a 59-year-old Perth resident who works in the financial industry, was able to access Recce’s R327 compound last year under Australia’s Special Access Scheme, a pathway for unapproved medicine used to treat potentially deadly conditions. In a phone interview late last week, Fletcher told * he had been plagued by recurring sinusitis for about three decades, leaving him feeling “dead and exhausted”. At first standard antibiotic treatments had been able to treat it, but eventually, the pseudomonas aeruginosa bacterium developed a lipid outer layer that made it resistant to the usual drugs.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)